A Multicenter International Follow-up Study to Monitor the Efficacy and Safety of the Occlutech PmVSD Occluder in Patients With Perimembranous Ventricular Septal Defects

  • End date
    Jul 27, 2026
  • participants needed
  • sponsor
    Occlutech International AB
Updated on 27 January 2021


The objective of this registry is to gain more insight on the clinical use of the Occlutech perimembranous VSD occluder.

Condition Perimembranous Ventricular Septal Defect
Clinical Study IdentifierNCT04034498
SponsorOcclutech International AB
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

Patients with haemodynamically significant perimembranous defects which are
located in the ventricular septum

Exclusion Criteria

Occlutech PmVSD Occluder is contraindicated for the following
Patients with defects less than 2 mm aortic rim and/or interference with the aortic or atrioventricular valves
Patients less than 10.0 kg
Patients with sepsis (local or generalized)
Patients with left ventricle to right atrial shunting
Patients with right to left shunting through the defect
Patients with PmVSD with an aneurysm and multiple shunts that could not be successfully closed with one device
Patients with complex heart lesions such as tetralogy of fallot
History of repeated pulmonary infection
Any type of serious infection 1 month prior to procedure
Malignancy where life expectancy is less than 3 years
Demonstrated intracardiac thrombi on echocardiography
Patients with allergy to anti-platelet or anticoagulant therapy
Patients with allergy to nickel and/or titanium and/or nickel/titanium based materials
Patients with intolerance to contrast agents
Patients with active bacterial infections
Patients with very small vessels which are not suitable for recommended delivery sheath sizes
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note